Updated NICE guidance on hypertension published

NICE has published an update to its guideline on the diagnosis and management of hypertension in adults (NG136). The new guidance replaces CG127, published in 2011.
The definition of hypertension in the new guidance is unchanged, for example Stage 1 hypertension is still defined as a …

More details...

NICE publishes draft guideline on use of medical cannabis

Following a review of clinical and cost-effectiveness, NICE has published draft guidance for consultation on the use of cannabis-based medicinal products for treatment of nausea and vomiting, chronic pain, spasticity and epilepsy.
The guidance was fast-tracked following the UK government’s re-classification of cannabis-based medicinal products from …

More details...

New antimicrobial prescribing guidance for impetigo

NICE is consulting on draft guidance on the treatment of impetigo. The recommendations will form part of NICE and Public Health England’s series of antimicrobial prescribing guidelines, which offer evidence-based prescribing advice to help tackle antimicrobial resistance.
Impetigo is a superficial bacterial infection of the skin …

More details...

Fast-acting insulin aspart approved for children

The European Commission has granted an extension to the indication of Fiasp (fast-acting insulin aspart). It is now approved for the treatment of diabetes in adolescents and children aged one year and above. Previously, it was licensed only for use in adults with diabetes (type …

More details...

Toolkit launched for progressive neurological conditions

NHS England has launched a new toolkit to support commissioners to improve services for patients with progressive neurological conditions.
The NHS RightCare Progressive Neurological Conditions Toolkit, which was developed in collaboration with NICE, the Motor Neurone Disease Association, the MS Society, the MS Trust, the Multiple …

More details...

Cannabidiol approved for Lennox-Gastaut syndrome and Dravet syndrome

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the cannabidiol preparation Epidyolex for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two severe forms of epilepsy.
Epidyolex will …

More details...

Inhaled levodopa recommended for ‘off’ episodes in Parkinson’s disease

The CHMP has issued a positive opinion, recommending the marketing authorisation of Inbrija (levodopa inhalation powder) for the treatment of symptoms of ‘off’ periods in Parkinson’s disease.
Inbrija is formulated as hard capsules containing an inhalation powder (containing 33mg levodopa) to be used with an oral …

More details...

Fingolimod now contraindicated in pregnancy

The EMA has issued new restrictions on the multiple sclerosis (MS) medicine fingolimod (Gilenya), recommending that it must not be used in pregnant women or in women of childbearing potential who are not using effective contraception.
Fingolimod is an oral disease-modifying therapy used for the treatment …

More details...

Dapagliflozin gains NICE approval for type 1 diabetes

In a final appraisal determination, NICE has recommended the SGLT2 inhibitor dapagliflozin (Forxiga) in combination with insulin for the management of certain patients with type 1 diabetes.
Dapagliflozin is recommended in adults with type 1 diabetes with a BMI of ≥27, when insulin alone does not …

More details...

NICE recommends risankizumab for severe plaque psoriasis

NICE has issued a final appraisal determination, recommending risankizumab (Skyrizi) as a treatment option for plaque psoriasis in adults.
The technology appraisal guidance recommends rizankizumab only if the disease is severe (defined as a Psoriasis Area and Severity Index [PASI] ≥10 and a Dermatology Life Quality …

More details...

Web design and marketing agency Leamington Spa